Anorexia Nervosa Treatment Market Size, Share, Trends, and Technological Growth From 2023 to 2032

0
22

According to a new report published by K D Market Insights, titled, “Anorexia Nervosa Treatment Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global anorexia nervosa treatment market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of anorexia nervosa, advancements in treatment options, and favorable government initiatives and support. Additionally, continuous investments in research and development (R&D) activities and the adoption of advanced technologies in the treatment of anorexia nervosa which are the major factors augmenting the growth of the global anorexia nervosa treatment market. The global anorexia nervosa treatment market is anticipated to grow at a high CAGR of 6.5% from 2023 to 2032. The market’s revenue surged to $4 billion in 2022, and it is expected to further accelerate, reaching a notable $7.5 billion by 2032.

There has been an increased prevalence of dietary health disorders, including anorexia nervosa, as more individuals seek help for their eating behavior patterns it is further expected to create ample growth opportunities for the global anorexia nervosa treatment market during the forecast period i.e., 2023-2032. Moreover, the rising awareness and improved healthcare education regarding eating disorders has propelled market expansion. Advancements in medical research and the development of innovative treatment approaches, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global anorexia nervosa treatment market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to region’s unhealthy lifestyle prevalent among a substantial population.

According to type of treatment, the psychological therapy segment accounted for the largest market share in the anorexia nervosa treatment market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global anorexia nervosa treatment market is segmented into type of treatment, application and region. Based on type of treatment, the market is bifurcated into psychological therapy, pharmacologic therapy, and others. Based on application, it is classified into hospitals, clinics, homecare, and others.

The global anorexia nervosa treatment market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Anorexia Nervosa Treatment Market

  • On the basis of type of treatment, the psychological therapy segment accounted for the largest market share in the anorexia nervosa treatment market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
  • On the basis of region, North America accounted for the largest share in the global anorexia nervosa treatment market in 2022. The region is further projected to continue dominating in the market during the forecast period.
  • On the basis of region, Europe is estimated to account for the second largest share in the market during the forecast period.

Some of the major anorexia nervosa treatment companies profiled in the report include AstraZeneca, Pfizer, Timberline Knolls, EDH, NEDC, Eating Disorders Victoria, and National Association of Anorexia Nervosa.

Related Reports :-

https://www.kdmarketinsights.com/reports/dementia-care-products-market/7375

https://www.kdmarketinsights.com/reports/cryoablation-devices-market/7374

https://www.kdmarketinsights.com/reports/glioblastoma-multiforme-treatment-market/7373

https://www.kdmarketinsights.com/reports/glycomics-market/7372